SBRT + Immunomodulating Systemic Therapy for Inoperable, Recurrent H&N

Head and Neck Neoplasm Clinical Trial

Official title:

Combined Hypofractionated Stereotactic Body Radiotherapy With Immunomodulating Systemic Therapy for Inoperable Recurrent Head and Neck Cancer: Detection of the Maximum Tolerated Dose.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03402737
• Other study ID #: EC/2017/0636
• Secondary ID: 2017-000133-31
• Status: Terminated
• Phase: N/A
• Start date: July 31, 2017
• Est. completion date: December 3, 2020

Study information

• Verified date: February 2021
• Source: University Hospital, Ghent
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To derive the maximum tolerated dose of hypofractionated stereotactic body radiotherapy (SBRT) using dose painting by numbers with immunomodulating systemic therapy in patients that are reirradiated for recurrent squamous cell carcinoma of the head and neck.

Description:

The standard treatment in inoperable locally or regionally recurrent head and neck cancer has long been palliative systemic therapy using the so-called EXTREME-scheme: a combination of cisplatin, 5-fluorouracil and cetuximab. This therapy remains without realistic chances of cure. More recently, immunotherapy using nivolumab has demonstrated to result in long-term disease control of 1-2 year in cisplatin-refractory recurrent or metastatic head and neck cancer, however only in a small portion of patients (13%).

Fractionated high-dose local or regional re-irradiation is mostly given in a 6-7 weeks scheme. Using stereotactic body radiotherapy (SBRT), high radiotherapy doses can be given in a short time span. Severe late adverse events have been reported using SBRT but seem less frequent than in patients re-treated with conventional schedules. A possible solution to be able to administer higher doses is combining SBRT with dose painting, thus giving these high doses on small subvolumes only.

Addition of concomitant therapy to reirradiation may further improve outcomes due to radiosensitization and direct cytotoxicity. Therefore the investigator aims to combine high doses with concomitant therapy in the proposed study.

The immunomodulatory effect caused by radiation has been demonstrated both in animal models and clinical trials and leads to an enhanced local control as well as to eradication of distant metastasis. This so-called abscopal effect is reached through a systemic immune response evoked by the release of damage-associated molecular patterns (DAMPs) by the dying tumor-cells, also called immunogenic cell death (ICD).

The investigator hypothesizes that an abscopal effect could be present for patients presenting locoregional recurrent disease with asymptomatic distant metastases, thereby offering at least symptom control at the primary site while palliative systemic treatment could be postponed.

The proposed protocol focuses on patients with bad prognosis, as determined by a short timespan between primary therapy and recurrence (defined as 6-24 months after the end of the primary radiotherapy). It would bring the practical advantage of only 2-3 patient visits for the radiotherapy instead of ± 30-35 visits over 6-7 weeks. This shorter treatment schedule is expected to result in a direct gain in quality-of-life due to locoregional symptom control. It can also be expected that rescue systemic therapy will be postponed to a later stage of disease development, thereby prolonging overall survival.

The combination with systemic agents that are involved in immunogenic cell death bear the potential to result in a higher number of patients with longer periods of disease control and survival. The current standard of care, i.e. the combined systemic treatment with cisplatin - 5-fluorouracil - cetuximab, or nivolumab in case of former cisplatin use, can be used as a rescue regimen in case of therapy failure. In that sense, better overall survival from time of diagnosis of the index locoregional recurrent disease is expected.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: December 3, 2020
• Est. primary completion date: December 3, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed local, regional or combined locoregional recurrence of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx or cancer of unknown primary (CUP) in the neck in previously irradiated tissue, with former irradiation with curative intent.

• Patients with non-symptomatic distant metastases and local, regional or combined locoregional recurrence can be included.

• In case of non-metastatic disease, the recurrence must be primarily unresectable recurrence and/or patients refused surgery.

• Time interval 6-24 months after the end of the initial radio(chemo)therapy for primary head and neck cancer.

• Decision of the Head and Neck Tumor Boards at the recruiting centre to offer salvage radio(chemo)therapy, palliative chemotherapy or anti-PD-1 antibody treatment with nivolumab for cisplatin-refractory locoregional recurrent head and neck squamous cell carcinoma.

• Karnofsky performance status = 70.

• Age = 18 years old.

• Informed consent obtained, signed and dated before specific protocol procedures.

Exclusion Criteria:

• Previous radiotherapy was for cT1-2 cN0 M0 glottic cancer.

• Grade = 4 late toxicity after the initial radio(chemo)therapy.

• Brachytherapy as treatment for second primary / recurrence.

• Previous (combination with) immunotherapy for the primary or the recurrent squamous cell carcinoma.

• Impossibility of oral intake of cyclophosphamide.

• For patients receiving cyclophosphamide: necessary intake during therapy of allopurinol, amiodarone, digoxin, hydrochlorothiazide, indomethacin, phenobarbital, phenytoin, warfarin. clopidogrel, ticlopidine, carbamazepine, efavirenz, rifampicin, ritonavir

• High risk for arterial blow-out: 1 of following criteria is sufficient to exclude patients:

1. soft tissue necrosis

2. skin invasion of the recurrent cancer

3. circumferential involvement of > 180° of a carotid artery

• Symptomatic distant metastases.

• Other uncontrolled second primary tumors.

• Pregnant or lactating women.

• Mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study.

• Patient unlikely to comply with protocol, i.e. uncooperative attitude, inability to return for follow-up visits, and unlikely to complete the study.

Related Conditions & MeSH terms

• Head and Neck Neoplasm
• Head and Neck Neoplasms

Intervention

Radiation:
• Stereotactic body radiotherapy
The range of dose-painting will be escalated in following levels: 2x 6-8Gy (day 1-4) 3x 6-8Gy (day 1-4-7) 3x 6-10Gy (day 1-4-7) 3x 6-12Gy (day 1-4-7) Patients will take cyclophosphamide orally 50 mg tablets, 1 tablet a day from the first day of irradiation for 8 consecutive weeks. Nivolumab will be considered as standard therapy in patients with cisplatin refractory locoregional disease recurrence. Nivolumab will be administered as per current standard of care. In case patients that are treated with nivolumab will be included in the trial, they will not be treated with cyclophosphamide.

Locations

Country	Name	City	State
Belgium	Radiotherapy department, University Hospital Ghent	Ghent	Oost-Vlaanderen
Belgium	UZ Leuven	Leuven
Belgium	CHU Namur	Namur

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	maximum tolerated dose	maximum tolerated dose of hypofractionated stereotactic body radiotherapy (SBRT) using dose painting by numbers with immunomodulating systemic therapy in patients that are reirradiated for recurrent squamous cell carcinoma of the head and neck	3 months after radiotherapy
Secondary	symptom palliation - pain	reduction in pain	through study completion, an average of 12 months
Secondary	symptom palliation - dysphagia	reduction in grade of dysphagia	through study completion, an average of 12 months
Secondary	local control	Assessment of: diameter of target lesion of SBRT (and, if present, non-target lesions) in mm; tumor response according to recist criteria	3 months after SBRT and thereafter through study completion, an average of 12 months
Secondary	Overall survival	To estimate overall survival	through study completion, an average of 12 months
Secondary	Progression free survival	To estimate progression-free survival	through study completion, an average of 12 months
Secondary	grade = 3 toxicity-free survival	To estimate grade = 3 toxicity-free survival (anemia, febrile neutropenia, fatigue, dysphagia, oral mucositis, laryngeal mucositis, pharyngeal mucositis, pharyngeal hemorrhage, pharyngeal necrosis, pharyngeal stenosis, pharyngolaryngeal pain, dry mouth)	through study completion, an average of 12 months
Secondary	QOL - general	To assess quality-of-life: EORTC QLQ	before therapy, week 3, week 6, week 10, week 14
Secondary	QOL - H&N specific	To assess quality-of-life: H&N35	before therapy, week 3, week 6, week 10, week 14
Secondary	topographic distribution of recurrence	To assess the topographic distribution of recurrence (inside/outside FDG-avid GTV)	through study completion, an average of 12 months
Secondary	time to further treatment	To assess time to further treatment	through study completion, an average of 12 months
Secondary	immune response	To assess the immune response	using serum taken before treatment and at each fraction of SBRT, at weeks 6-14